Payment overview · 2025
General Payments
$567.53
34 reported records · 5 companies
Healthcare provider profile · identity verified
Craig A Maier, MD
Allopathic & Osteopathic Physicians|Family Medicine · DELMAR, NY · NPI 1871751925
Verified facts
What the public records show
CMS Open Payments records show Craig A Maier, MD received $567.53 in general payments during 2025 across 34 reported records.
GlaxoSmithKline, LLC. accounted for 43.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $243.89 | 43.0% | 20 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $144.21 | 25.4% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $113.57 | 20.0% | 5 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $34.92 | 6.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $30.94 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $567.53 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $132.54 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $113.57 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $113.57 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $112.74 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $111.35 | 11 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $111.06 | 5 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $34.92 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.15 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $30.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 37 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 883 | 254 |
| Omeprazole | Omeprazole | 438 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 271 | 84 |
| Lisinopril | Lisinopril | 193 | 59 |
| Metformin Hcl | Metformin Hcl | 163 | 46 |
| Losartan Potassium | Losartan Potassium | 161 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 140 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 40 |
| Sertraline Hcl | Sertraline Hcl | 119 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 33 |
| Metformin Hcl Er | Metformin Hcl | 102 | 28 |
| Celecoxib | Celecoxib | 100 | 40 |
| Alendronate Sodium | Alendronate Sodium | 98 | 29 |
| Allopurinol | Allopurinol | 94 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 34 |
| Famotidine | Famotidine | 93 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 38 |
| Prednisone | Prednisone | 84 | 61 |
| Glipizide | Glipizide | 81 | 20 |
| Gabapentin | Gabapentin | 76 | 28 |
| Tradjenta | Linagliptin | 76 | 17 |
| Alprazolam | Alprazolam | 75 | 27 |
| Jardiance | Empagliflozin | 75 | 17 |
| Synthroid | Levothyroxine Sodium | 66 | 16 |
| Ezetimibe | Ezetimibe | 64 | 19 |
| Chlorthalidone | Chlorthalidone | 60 | 18 |
| Trazodone Hcl | Trazodone Hcl | 60 | 18 |
| Mounjaro | Tirzepatide | 59 | suppressed |
| Trulicity | Dulaglutide | 57 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 16 |
| Simvastatin | Simvastatin | 55 | 19 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 54 | 50 |
| Valacyclovir | Valacyclovir Hcl | 54 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 12 |
| Buspirone Hcl | Buspirone Hcl | 45 | 14 |
| Atenolol | Atenolol | 44 | 11 |
| Bupropion Xl | Bupropion Hcl | 44 | 16 |
| Doxepin Hcl | Doxepin Hcl | 43 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 17 |
| Furosemide | Furosemide | 39 | 14 |
| Irbesartan | Irbesartan | 38 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 13 |
| Eliquis | Apixaban | 37 | 11 |
| Glipizide Er | Glipizide | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | 11 |
| Pregabalin | Pregabalin | 27 | 11 |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 15 |
| Meclizine Hcl | Meclizine Hcl | 22 | 16 |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Carbamazepine Er | Carbamazepine | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 12 |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 12 |
| Belsomra | Suvorexant | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $567.53 · 34 records | GlaxoSmithKline, LLC. | AREXVY, Cologuard Collection Kit, ELIQUIS, QULIPTA, SHINGRIX, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error